Product Launch and Market Potential - Citius Oncology launched LYMPHIR™, a novel immunotherapy, in the U.S. in December 2025 for treating adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy[3] - The initial market for LYMPHIR is estimated to exceed $400 million, indicating significant growth potential in an underserved market[5] - Citius Oncology secured access to LYMPHIR in 19 international markets through regional distribution partners via Named Patient Programs, marking a step in its global access strategy[6] - The company executed service agreements with three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to healthcare organizations across the U.S.[3] - Citius Oncology announced a collaboration with Verix to enhance commercial targeting and provider engagement for LYMPHIR's U.S. commercialization[6] Financial Performance - The net loss for the fiscal year ended September 30, 2025, was $24.8 million, or ($0.34) per share, compared to a net loss of $21.1 million, or ($0.31) per share, in 2024[6] - Net loss for 2025 was $(24,761,369), compared to $(21,148,747) in 2024, indicating a worsening financial position[16] - Cash and cash equivalents stood at $3.9 million as of September 30, 2025, compared to $112 in 2024[11] - Stock-based compensation expense increased to $8,320,419 in 2025 from $7,498,817 in 2024, reflecting higher employee compensation costs[16] - Inventory changes resulted in a significant increase of $(12,649,207) in 2025, compared to $(2,133,871) in 2024, indicating potential overstock issues[16] Cash Flow and Financing Activities - Net cash used in operating activities was $(5,492,046) in 2025, a decline from a positive cash flow of $126,353 in 2024[16] - Net cash provided by financing activities rose to $15,166,842 in 2025, up from $4,873,759 in 2024, showing increased capital raising efforts[16] - Cash and cash equivalents at the end of 2025 were $3,924,908, a significant increase from $112 at the beginning of the year[16] - License payments for 2025 amounted to $(5,750,000), consistent with $(5,000,000) in 2024, indicating ongoing investment in licenses[16] - Interest paid in 2025 was $187,389, while no interest was reported in 2024, suggesting new debt obligations[16] Expenses Overview - Research and development expenses increased to $6.4 million for the fiscal year ended September 30, 2025, up from $4.9 million in 2024[6] - General and administrative expenses rose to $8.8 million for the fiscal year ended September 30, 2025, compared to $8.1 million in 2024[6] - The company reported a capital contribution of due to related party by parent of $33,180,961 in 2024, which was not repeated in 2025[16] - Net prepaid manufacturing transferred to inventory was $1,368,720 in 2025, down from $6,134,895 in 2024, indicating a shift in production strategy[16]
Citius Oncology, Inc.(CTOR) - 2025 Q3 - Quarterly Results